Travere Therapeutics, Inc. filings document a rare-disease biopharmaceutical issuer whose disclosures center on FILSPARI (sparsentan), operating results, FDA regulatory events, and public-company governance. Recent 8-K reports furnish quarterly and annual financial results and disclose regulatory events involving FILSPARI in focal segmental glomerulosclerosis and IgA nephropathy.
Proxy materials cover annual meeting voting, board matters, executive compensation, equity awards, and stockholder governance. The filing record also documents formal event reporting under the Exchange Act for product-regulatory updates and financial-condition disclosures.
Travere Therapeutics SVP and Chief Accounting Officer Calvin Sandra reported equity awards and a tax-related stock sale. On January 31, 2026, she received 15,180 shares of common stock through vested restricted stock units and an employee stock option for 20,160 shares at an exercise price of $33.095 per share.
On February 3, 2026, she sold 4,333 shares of common stock at $32.12 per share to cover tax withholding from the RSU settlement, a mandated "sell to cover" transaction rather than a discretionary trade. After these transactions, she directly owned 49,080 shares of common stock and 20,160 stock options.
Travere Therapeutics' chief legal officer, Elizabeth E. Reed, reported routine equity compensation and a related tax sale. On 01/31/2026 she received 25,110 shares of common stock for $0 as restricted stock units settled, bringing her direct holdings to 115,380 shares. On 02/03/2026, 7,175 shares were sold at $32.12 solely to cover tax withholding on the vesting; the company’s plan requires this mandated “sell to cover” transaction, so it was not a discretionary trade. She also received an employee stock option on 01/31/2026 for 66,960 shares at an exercise price of $33.095, vesting 25% after one year and the remainder in 36 monthly installments, giving her 66,960 options directly held.
Travere Therapeutics insider plans additional share sale under Rule 144. A person identified as Eric M. Dube has filed to sell 100,087 shares of common stock of Travere Therapeutics through Fidelity Brokerage Services on NASDAQ, with an approximate sale date of 02/03/2026 and an aggregate market value of $3,289,859.69. The filing notes 89,472,327 common shares outstanding.
The 100,087 shares were acquired on 02/02/2026 via restricted stock vesting from the issuer as compensation, with payment also dated 02/02/2026. Over the prior three months, the same seller completed two sales of Travere common stock totaling 8,135 and 51,865 shares, generating gross proceeds of $244,153.28 and $1,560,982.50.
A Rule 144 notice covers a planned sale of 12,446 shares of common stock of the issuer on 02/03/2026 through Fidelity Brokerage Services LLC on the NASDAQ, with an aggregate market value of $409,100.02. The filing reports that 89,472,327 shares of this class were outstanding.
The seller, William E. Rote, acquired these 12,446 shares on 02/02/2026 via restricted stock vesting from the issuer as compensation. The notice also discloses that he sold 60,000 common shares on 12/24/2025 for gross proceeds of $2,406,178.52.
Travere Therapeutics CEO Eric M. Dube reported planned option exercises and related stock sales under a Rule 10b5-1 trading plan adopted on June 16, 2025. On January 23 and January 27, 2026, he exercised employee stock options for a total of 60,000 shares of common stock at an exercise price of $15.46 per share and sold the same number of shares at weighted average prices of $30.0127 and $30.097, respectively. Following these transactions, he held 419,173 shares of Travere common stock directly, and continued to hold fully vested employee stock options with a $15.46 exercise price expiring on January 31, 2030, including positions of 171,865 and 120,000 options.
Eric M. Dube has filed a notice of proposed sale of TVTX common stock under Rule 144. The filing covers 51,865 common shares to be sold through Fidelity Brokerage Services on NASDAQ, with an aggregate market value of 1,560,982.50. The issuer has 89,472,327 shares of common stock outstanding. The shares to be sold were acquired on 01/27/2026 through the cash exercise of an option originally granted on 01/31/2020.
The notice also lists prior sales of the issuer’s common stock by Dube during the past three months. These include 92,872 shares sold on 10/28/2025 for 2,821,217.14, 27,128 shares sold on 10/29/2025 for 817,045.37, and 8,135 shares sold on 01/23/2026 for 244,153.28. By signing, the seller represents that he is not aware of undisclosed material adverse information about the issuer’s current or prospective operations.
Travere Therapeutics insider plans another stock sale. A person identified in the filing plans to sell 8,135 shares of Travere Therapeutics common stock through Fidelity Brokerage Services on NASDAQ, with an aggregate market value of 244,153.28, when 89,472,327 shares were outstanding as of the notice. The shares were acquired on 01/23/2026 via an option granted on 01/31/2020 and paid for in cash.
Over the prior three months, Eric M. Dube at a San Diego address sold 92,872 Travere common shares on 10/28/2025 for 2,821,217.14 and 27,128 shares on 10/29/2025 for 817,045.37. The signer represents they are not aware of any undisclosed material adverse information about the issuer’s current or prospective operations.
Travere Therapeutics Chief Legal Officer Elizabeth E. Reed reported an option exercise and share sale in Travere Therapeutics, Inc. common stock. On January 20, 2026, she exercised 10,000 employee stock options at an exercise price of $19.08 per share and received 10,000 shares of common stock.
That same day, she sold 10,000 shares of Travere common stock at a weighted average price of $27.3420 per share under a Rule 10b5-1(c) trading plan adopted on June 16, 2025, tied to a stock option grant from January 4, 2017 that expires on January 4, 2027. After these transactions, she directly beneficially owned 90,270 shares of common stock, which include 392 shares acquired through the 2017 Employee Stock Purchase Plan, and held 30,000 employee stock options that are fully vested and exercisable.
A holder of TVTX common stock has filed a notice to sell 10,000 shares under Rule 144. The shares are to be sold through Morgan Stanley Smith Barney LLC on the NASDAQ, with an indicated aggregate market value of $273,420.00. The filing shows 89,472,327 shares of this class outstanding.
The 10,000 shares were acquired from the issuer on 01/20/2026 through a stock option exercise paid in cash on the same date, and are the securities covered by this planned sale.
Travere Therapeutics reported that the U.S. FDA has extended the review timeline for its supplemental New Drug Application for FILSPARI (sparsentan) in focal segmental glomerulosclerosis (FSGS). The new PDUFA target action date is April 13, 2026, following the company’s recent submission of additional information requested by the FDA to further characterize FILSPARI’s clinical benefit.
The FDA classified the submission as a Major Amendment to the application and extended the review period accordingly, and has not requested any new safety or manufacturing data. If ultimately approved, FILSPARI would be the first medication indicated for FSGS, a rare kidney disease with no FDA-approved pharmacologic therapies, and would add to FILSPARI’s existing full approvals in the U.S. and EU for slowing kidney function decline in adults with IgA nephropathy.